HRP20191449T1 - Anti-b7-h1 i anti-ctla-4 protutijela za liječenje raka pluća ne-malih stanica - Google Patents
Anti-b7-h1 i anti-ctla-4 protutijela za liječenje raka pluća ne-malih stanica Download PDFInfo
- Publication number
- HRP20191449T1 HRP20191449T1 HRP20191449T HRP20191449T1 HR P20191449 T1 HRP20191449 T1 HR P20191449T1 HR P20191449 T HRP20191449 T HR P20191449T HR P20191449 T1 HRP20191449 T1 HR P20191449T1
- Authority
- HR
- Croatia
- Prior art keywords
- combination
- use according
- antigen
- binding fragment
- nsclc
- Prior art date
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 229950009791 durvalumab Drugs 0.000 claims 6
- 229950007217 tremelimumab Drugs 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- -1 Bevacizumab Chemical compound 0.000 claims 1
- 190000008236 Carboplatin Chemical compound 0.000 claims 1
- 206010069755 K-ras gene mutation Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (17)
1. Kombinacija koja sadrži MEDI4736, ili njegov fragment koji veže antigen, i tremelimumab, ili njegov fragment koji veže antigen, naznačena time što je za uporabu u liječenju NSCLC kod ljudskog pacijenta, pri čemu se MEDI-4736 primjenjuje u dozi od 20 mg/kg svaka 4 tjedna, a tremelimumab se daje pacijentu u dozi od 1 mg/kg.
2. Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što se odgovor tumora može otkriti do 2, 4, 6, 8, 10, 33 ili 50-tog tjedna.
3. Kombinacija za uporabu prema patentnom zahtjevu 1 ili 2 , naznačena time što primjene povećavaju preživljavanje bez progresije.
4. Kombinacija za uporabu prema patentnom zahtjevu 3, naznačena time što primjene rezultiraju povećanjem preživljenja bez progresije u usporedbi s primjenama bilo samog MEDI4736, ili njegovog fragmenta koji veže antigen, ili samog tremelimumaba, ili njegovog fragmenta koji veže antigen.
5. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-4, naznačena time što je NSCLC otporan na najmanje jedno kemoterapijsko sredstvo.
6. Kombinacija za uporabu prema patentnom zahtjevu 5, naznačena time što je kemoterapijsko sredstvo Vemurafenib, Erlotinib, Afatinib, Cetuksimab, Karboplatin, Bevacizumab, Erlotinib, Gefitinib, ili Pemetreksed.
7. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačena time što pacijent ima status uspješnosti Eastern Cooperative Oncology Group (ECOG) od 0-1.
8. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačena time što pacijent nije primao imunoterapiju prije davanja MEDI4736 ili njegovog fragmenta koji veže antigen i tremelimumaba ili njegovog fragmenta koji veže antigen.
9. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-8, naznačena time što se davanje MEDI4736 ili njegovog fragmenta koji veže antigen provodi putem intravenske infuzije.
10. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-9, naznačena time što se davanje tremelimumaba ili njegovog fragmenta koji veže antigen provodi putem intravenske infuzije.
11. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-10, naznačena time što primjene smanjuju veličinu tumora za najmanje oko 10%, 25% ili 50% u odnosu na baznu liniju.
12. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-11, naznačena time što human pacijent ima lokalno uznapredovali neresektabilni ili metastatski NSCLC.
13. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-12, naznačena time što je NSCLC skvamozan ili ne-skvamozan.
14. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-13, naznačena time što NSCLC obuhvaća KRAS-mutaciju ili EGFR-mutaciju.
15. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-14, naznačena time što je NSCLC PD-L1 pozitivan.
16. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-14, naznačena time što je NSCLC PD-L1 negativan.
17. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 1-16, naznačena time što se MEDI4736 primjenjuje svakih 4 tjedna tijekom 49 tjedana.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461992658P | 2014-05-13 | 2014-05-13 | |
US201562105992P | 2015-01-21 | 2015-01-21 | |
US201562114336P | 2015-02-10 | 2015-02-10 | |
PCT/EP2015/060523 WO2015173267A1 (en) | 2014-05-13 | 2015-05-12 | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
EP15722195.3A EP3142751B1 (en) | 2014-05-13 | 2015-05-12 | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191449T1 true HRP20191449T1 (hr) | 2019-11-15 |
Family
ID=53175516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191449 HRP20191449T1 (hr) | 2014-05-13 | 2019-08-09 | Anti-b7-h1 i anti-ctla-4 protutijela za liječenje raka pluća ne-malih stanica |
Country Status (26)
Country | Link |
---|---|
US (3) | US10232040B2 (hr) |
EP (2) | EP3142751B1 (hr) |
JP (4) | JP6648038B2 (hr) |
KR (4) | KR20230165876A (hr) |
CN (2) | CN106456756B (hr) |
AU (3) | AU2015260962B2 (hr) |
BR (2) | BR112016026197A2 (hr) |
CA (1) | CA2947471A1 (hr) |
CY (1) | CY1122642T1 (hr) |
DK (1) | DK3142751T3 (hr) |
ES (1) | ES2749098T3 (hr) |
GB (1) | GB2531094A (hr) |
HR (1) | HRP20191449T1 (hr) |
HU (1) | HUE045965T2 (hr) |
IL (2) | IL248528B (hr) |
LT (1) | LT3142751T (hr) |
ME (1) | ME03493B (hr) |
MX (1) | MX2016014189A (hr) |
PL (1) | PL3142751T3 (hr) |
PT (1) | PT3142751T (hr) |
RS (1) | RS59134B1 (hr) |
RU (1) | RU2702332C2 (hr) |
SG (2) | SG11201609285SA (hr) |
SI (1) | SI3142751T1 (hr) |
TW (3) | TWI780994B (hr) |
WO (1) | WO2015173267A1 (hr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210143932A (ko) * | 2013-09-11 | 2021-11-29 | 메디뮨 리미티드 | 종양 치료용 항-b7-h1 항체 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
GB2531094A (en) * | 2014-05-13 | 2016-04-13 | Medimmune Ltd | Anti-B7-H1 and Anti-CTLA-4 antibodies for treating non-small cell lung cancer |
GB2535256A (en) * | 2014-08-28 | 2016-08-17 | Medimmune Ltd | Combination therapy for PD-L1 negative tumors |
WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
RU2018140960A (ru) | 2016-04-25 | 2020-05-26 | МЕДИММЬЮН, ЭлЭлСи | Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4 |
CN109790583B (zh) * | 2016-05-17 | 2023-08-25 | 基因中心治疗公司 | 对肺腺癌亚型分型的方法 |
CA3024744A1 (en) * | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung squamous cell carcinoma |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
AU2017281830B2 (en) | 2016-06-20 | 2023-04-06 | Kymab Limited | Anti-PD-L1 antibodies |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
EP3510048A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Methods of treating pd-l1 expressing cancer |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US20190256603A1 (en) * | 2016-11-11 | 2019-08-22 | Medimmune, Llc | Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
EA201991870A1 (ru) * | 2017-02-16 | 2020-02-12 | МЕДИММЬЮН, ЭлЭлСи | Лечение рака мочевого пузыря с помощью антитела к pd-l1 |
EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
CA3092632A1 (en) * | 2018-03-08 | 2019-09-12 | Astrazeneca Ab | Compositions and methods for treating late stage lung cancer |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
JP7487558B2 (ja) | 2020-05-25 | 2024-05-21 | 船井電機株式会社 | 面光源装置および表示装置 |
JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Hpv陽性癌の治療用rna |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
TW202313682A (zh) | 2021-05-18 | 2023-04-01 | 英商凱麥博有限公司 | 抗icos抗體之用途 |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023077069A1 (en) * | 2021-10-29 | 2023-05-04 | OncoC4, Inc. | Anti-ctla-4 antibody dosing regimens |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7158164B2 (en) | 2003-08-29 | 2007-01-02 | Fuji Photo Film Co., Ltd. | Thermal development method and apparatus |
AU2011203119C1 (en) | 2005-05-09 | 2018-06-14 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
US20100055111A1 (en) * | 2007-02-14 | 2010-03-04 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
CN102000947B (zh) * | 2010-10-14 | 2012-06-06 | 沈阳飞机工业(集团)有限公司 | 两半轴瓦的铣切加工方法 |
KR20180129991A (ko) | 2010-11-05 | 2018-12-05 | 노파르티스 아게 | Il-17 길항제를 사용한 류마티스성 관절염의 치료 방법 |
CN101975831B (zh) * | 2010-11-25 | 2012-09-05 | 中国检验检疫科学研究院 | 高效液相色谱法测定化妆品中苯酚磺酸锌的方法 |
TWI496886B (zh) * | 2011-06-24 | 2015-08-21 | Taipei Veteran General Hospital | 提升感染性與惡性疾病之治療之免疫反應 |
WO2013169388A1 (en) | 2012-05-08 | 2013-11-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy |
US9846162B2 (en) * | 2012-05-14 | 2017-12-19 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
CA2873402C (en) * | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
US10034939B2 (en) * | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
US9107960B2 (en) * | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
LT2961388T (lt) * | 2013-03-01 | 2019-08-26 | Astex Pharmaceuticals, Inc. | Vaistų deriniai |
GB2531094A (en) * | 2014-05-13 | 2016-04-13 | Medimmune Ltd | Anti-B7-H1 and Anti-CTLA-4 antibodies for treating non-small cell lung cancer |
WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
PT3218406T (pt) * | 2014-11-10 | 2021-06-17 | Medimmune Ltd | Moléculas de ligação específicas para cd73 e seus usos |
EP3283107B1 (en) * | 2015-04-17 | 2020-05-27 | Bristol-Myers Squibb Company | Compositions comprising a combination of ipilimumab and nivolumab |
US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
EA201991870A1 (ru) * | 2017-02-16 | 2020-02-12 | МЕДИММЬЮН, ЭлЭлСи | Лечение рака мочевого пузыря с помощью антитела к pd-l1 |
-
2015
- 2015-05-12 GB GB1508097.1A patent/GB2531094A/en not_active Withdrawn
- 2015-05-12 CA CA2947471A patent/CA2947471A1/en active Pending
- 2015-05-12 PL PL15722195T patent/PL3142751T3/pl unknown
- 2015-05-12 KR KR1020237040802A patent/KR20230165876A/ko active Application Filing
- 2015-05-12 EP EP15722195.3A patent/EP3142751B1/en active Active
- 2015-05-12 SG SG11201609285SA patent/SG11201609285SA/en unknown
- 2015-05-12 KR KR1020167031692A patent/KR102333658B1/ko active IP Right Grant
- 2015-05-12 RU RU2016148645A patent/RU2702332C2/ru active
- 2015-05-12 WO PCT/EP2015/060523 patent/WO2015173267A1/en active Application Filing
- 2015-05-12 KR KR1020217038830A patent/KR20210149870A/ko not_active Application Discontinuation
- 2015-05-12 RS RS20191070A patent/RS59134B1/sr unknown
- 2015-05-12 AU AU2015260962A patent/AU2015260962B2/en active Active
- 2015-05-12 ES ES15722195T patent/ES2749098T3/es active Active
- 2015-05-12 US US14/710,101 patent/US10232040B2/en active Active
- 2015-05-12 CN CN201580024117.6A patent/CN106456756B/zh active Active
- 2015-05-12 PT PT157221953T patent/PT3142751T/pt unknown
- 2015-05-12 ME MEP-2019-231A patent/ME03493B/me unknown
- 2015-05-12 JP JP2016567088A patent/JP6648038B2/ja active Active
- 2015-05-12 BR BR112016026197-6A patent/BR112016026197A2/pt active IP Right Grant
- 2015-05-12 EP EP19190351.7A patent/EP3603748A1/en active Pending
- 2015-05-12 SG SG10201810108PA patent/SG10201810108PA/en unknown
- 2015-05-12 BR BR122023025321-3A patent/BR122023025321A2/pt unknown
- 2015-05-12 DK DK15722195.3T patent/DK3142751T3/da active
- 2015-05-12 HU HUE15722195A patent/HUE045965T2/hu unknown
- 2015-05-12 MX MX2016014189A patent/MX2016014189A/es active IP Right Grant
- 2015-05-12 SI SI201530857T patent/SI3142751T1/sl unknown
- 2015-05-12 LT LTEP15722195.3T patent/LT3142751T/lt unknown
- 2015-05-12 CN CN202110380316.8A patent/CN113230398A/zh active Pending
- 2015-05-12 KR KR1020227040764A patent/KR20220162844A/ko active Application Filing
- 2015-05-13 TW TW110144264A patent/TWI780994B/zh active
- 2015-05-13 TW TW109134952A patent/TW202123967A/zh unknown
- 2015-05-13 TW TW104115327A patent/TWI707692B/zh active
-
2016
- 2016-10-26 IL IL248528A patent/IL248528B/en active IP Right Grant
-
2019
- 2019-01-24 US US16/256,022 patent/US11446377B2/en active Active
- 2019-08-09 HR HRP20191449 patent/HRP20191449T1/hr unknown
- 2019-10-03 CY CY20191101034T patent/CY1122642T1/el unknown
-
2020
- 2020-01-15 JP JP2020004032A patent/JP2020090509A/ja active Pending
- 2020-08-04 IL IL276481A patent/IL276481B/en unknown
- 2020-09-10 AU AU2020230309A patent/AU2020230309B2/en active Active
-
2021
- 2021-03-10 JP JP2021037883A patent/JP2021098734A/ja active Pending
-
2022
- 2022-08-09 US US17/818,546 patent/US20230115328A1/en active Pending
-
2023
- 2023-01-25 JP JP2023009115A patent/JP7519477B2/ja active Active
- 2023-07-04 AU AU2023204286A patent/AU2023204286A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191449T1 (hr) | Anti-b7-h1 i anti-ctla-4 protutijela za liječenje raka pluća ne-malih stanica | |
MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
HRP20210440T1 (hr) | Kombinirana terapija za rak | |
HRP20192337T1 (hr) | Makrociklični inhibitori pd-1/pd-l1 i cd80(b7-1)/pd-l1 protein/protein interakcija | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
WO2017097723A3 (en) | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies | |
MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
IL278423B2 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
JP2017501155A5 (hr) | ||
JP2013173775A5 (hr) | ||
RU2017120063A (ru) | Терапевтические комбинации для лечения неоплазии | |
WO2015130554A3 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
IL292658A (en) | Immune modulation with tlr9 agonists for cancer therapy | |
JP2016183163A5 (hr) | ||
JP2017537927A5 (hr) | ||
JP2017514854A5 (hr) | ||
RU2016147521A (ru) | Способы применения антител к ang2 | |
MX2018010644A (es) | Nanoinmunoconjugados a base de acido polimalico y usos de los mismos. | |
BR112016016932A8 (pt) | uso de uma combinação de oxaliplatina (oxa), leucovorina (lv) e 5-fluorouracil (5-fu) | |
RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
WO2017181099A8 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |